Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Nobuaki Takeshita"'
Autor:
Yukari Koya, Hirotsugu Tanaka, Eiji Yoshimi, Nobuaki Takeshita, Shuji Morita, Hiroki Morio, Kanako Mori, Hiroshi Fushiki, Masazumi Kamohara
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTNerve growth factor (NGF) has emerged as a key driver of pain perception in several chronic pain conditions, including osteoarthritis (OA), and plays an important role in the generation and survival of neurons. Although anti-NGF antibodies im
Externí odkaz:
https://doaj.org/article/1d317d9198cb4f5ca6596cc78d7ab4ae
Autor:
Shingo Sugahara, Kaori Hanaoka, Takashi Emori, Nobuaki Takeshita, Yasutomo Fujii, Masaki Nakano, Takako Suzuki, Jun Takahashi, Yukio Nakamura
Publikováno v:
Journal of Pharmacological Sciences, Vol 148, Iss 1, Pp 134-141 (2022)
Peficitinib, a pan-JAK inhibitor, is known to suppress the activation of fibroblast-like synoviocytes (FLSs) and thereby reduces joint inflammation associated with rheumatoid arthritis (RA). However, the effect on osteoporosis in RA remains to be elu
Externí odkaz:
https://doaj.org/article/0f3811cf2f52458db0d2eb57ee8a9f18
Publikováno v:
Journal of Pharmacological Sciences, Vol 115, Iss 4, Pp 481-489 (2011)
The effects of AS1892802, a selective Rho-associated coiled coil kinase (ROCK) inhibitor, on knee cartilage damage and pain behavior were examined in a rat model of osteoarthritis (OA). Monoiodoacetate (MIA) was intraarticularly injected into the rig
Externí odkaz:
https://doaj.org/article/3386f2878e8a4b85b7fff0effff4bfdb
Publikováno v:
Journal of Pharmacological Sciences, Vol 114, Iss 1, Pp 119-122 (2010)
To assess the pharmacological profile of AS1892802, a novel and selective Rho kinase (ROCK) inhibitor, we examined the effects of repeated dosing with AS1892802 on models of monoiodoacetate-induced arthritis and streptozotocin-induced neuropathy. Alt
Externí odkaz:
https://doaj.org/article/448397a05b5349ecbde5e0025714cb4f
Publikováno v:
Biochemical and Biophysical Research Communications. 668:27-34
Autor:
Yukari Koya, Hirotsugu Tanaka, Eiji Yoshimi, Nobuaki Takeshita, Shuji Morita, Hiroki Morio, Kanako Mori, Hiroshi Fushiki, Masazumi Kamohara
Publikováno v:
mAbs. 15
Nerve growth factor (NGF) has emerged as a key driver of pain perception in several chronic pain conditions, including osteoarthritis (OA), and plays an important role in the generation and survival of neurons. Although anti-NGF antibodies improve pa
Autor:
Nobuaki Takeshita, Takashi Emori, Yasutomo Fujii, Shingo Sugahara, Jun Takahashi, Masaki Nakano, Kaori Hanaoka, Yukio Nakamura, Takako Suzuki
Publikováno v:
Journal of Pharmacological Sciences, Vol 148, Iss 1, Pp 134-141 (2022)
Peficitinib, a pan-JAK inhibitor, is known to suppress the activation of fibroblast-like synoviocytes (FLSs) and thereby reduces joint inflammation associated with rheumatoid arthritis (RA). However, the effect on osteoporosis in RA remains to be elu
Publikováno v:
European journal of pharmacology. 924
Pathological osteolysis is associated with excessive bone resorption by activated osteoclasts. Given that receptor activator of NF-kB and its ligand (RANKL) are key players in the differentiation and activation of osteoclasts, the RANKL/RANK signalin
Publikováno v:
Journal of Pain Research.
Nobuaki Takeshita, Tomoya Oe, Tetsuo Kiso, Shuichiro Kakimoto Drug Discovery Research, Astellas Pharma Inc, Ibaraki, JapanCorrespondence: Nobuaki TakeshitaDrug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
Publikováno v:
Journal of Pain Research
Purpose Although abnormal peripheral and central pain processing has been observed in fibromyalgia (FM) patients, the biomechanics and pathophysiology, surrounding the peripheral mechanism are not well understood. An intermediate conductance channel,